Denosumab increased 1/3 radius bone mineral density in postmenopausal women across randomized controlled clinical trials
Edward Franek(Mossakowski Medical Research Institute, Polish Academy of Sciences), Carol Zapalowski, R.B. Wagman(Amgen (United States)), E. Michael Lewiecki(New Mexico Clinical Research & Osteoporosis Center), Richard L. Prince(Edith Cowan University), I. Ferreira(Amgen (United States)), DL Kendler(Anna Needs Neuroblastoma Answers), José Zanchetta(Universidad del Salvador)
Cited by 0
Related Papers
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Clinician’s Guide to Prevention and Treatment of Osteoporosis
|Osteoporosis International|2014|4.1k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
|The Lancet|2019|3.1k
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
|New England Journal of Medicine|2014|1.2k